U.S. News & World Report Expands Use of Solventum's Ambulatory Potentially Preventable Complications Grouping Software for Use in Its 2024-2025 Best Hospitals Rankings
Solventum Co. (NYSE: SOLV) had its price target lowered by analysts at Bank of America Co. from $70.00 to $60.00. They now have a "neutral" rating on the stock.
Solventum introduces denials prevention solution, an AI-powered tool, empowering health systems to help reduce write-offs and improve top line revenue
Solventum Co. (NYSE: SOLV) is now covered by analysts at Argus. They set a "hold" rating on the stock.
Solventum Cautions Investors Regarding TRC Capital's "Mini-Tender Offer"